Image_6_Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome.JPEG (66.05 kB)

Image_6_Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome.JPEG

Download (66.05 kB)
figure
posted on 22.03.2019, 15:40 by Fergal J. Duffy, January Weiner, Scott Hansen, David L. Tabb, Sara Suliman, Ethan Thompson, Jeroen Maertzdorf, Smitha Shankar, Gerard Tromp, Shreemanta Parida, Drew Dover, Michael K. Axthelm, Jayne S. Sutherland, Hazel M. Dockrell, Tom H. M. Ottenhoff, Thomas J. Scriba, Louis J. Picker, Gerhard Walzl, Stefan H. E. Kaufmann, Daniel E. Zak, The GC6-74 Consortium

There remains a pressing need for biomarkers that can predict who will progress to active tuberculosis (TB) after exposure to Mycobacterium tuberculosis (MTB) bacterium. By analyzing cohorts of household contacts of TB index cases (HHCs) and a stringent non-human primate (NHP) challenge model, we evaluated whether integration of blood transcriptional profiling with serum metabolomic profiling can provide new understanding of disease processes and enable improved prediction of TB progression. Compared to either alone, the combined application of pre-existing transcriptome- and metabolome-based signatures more accurately predicted TB progression in the HHC cohorts and more accurately predicted disease severity in the NHPs. Pathway and data-driven correlation analyses of the integrated transcriptional and metabolomic datasets further identified novel immunometabolomic signatures significantly associated with TB progression in HHCs and NHPs, implicating cortisol, tryptophan, glutathione, and tRNA acylation networks. These results demonstrate the power of multi-omics analysis to provide new insights into complex disease processes.

History

References

Licence

Exports